• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    (OP:BNXTF)

    0.6000 UNCHANGED
    Streaming Delayed Price Updated: 1:05 PM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BNXTF

    < Previous 1 2 Next >
    BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
    Via ACCESSWIRE
    Terry Lynch Joins BioNxt as Capital Markets Advisor
    Via ACCESSWIRE
    BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
    Via ACCESSWIRE
    BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
    Via ACCESSWIRE
    BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
    Via ACCESSWIRE
    BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
    Via ACCESSWIRE
    BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
    Via ACCESSWIRE
    BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
    Via ACCESSWIRE
    BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
    Via ACCESSWIRE
    BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study
    Via Investor Brand Network
    Topics Intellectual Property
    BioNxt Reports Successful Results From ODF Cladribine PK Study
    Via ACCESSWIRE
    BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
    Via ACCESSWIRE
    BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
    Via ACCESSWIRE
    BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
    Via ACCESSWIRE
    BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
    Via ACCESSWIRE
    BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
    Via ACCESSWIRE
    BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
    Via ACCESSWIRE
    BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
    Via ACCESSWIRE
    BioNxt Successfully Completes Pilot Study for Contract Development Customer
    Via ACCESSWIRE
    BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
    Via ACCESSWIRE
    BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
    Via ACCESSWIRE
    BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology
    Via ACCESSWIRE
    BioNxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson’s Disease
    Via ACCESSWIRE
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.